ArticlePLoS neglected tropical diseases2025
Unsupervised machine learning identifies biomarkers of disease progression in post-kala-azar dermal leishmaniasis in Sudan.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPost-kala-azar dermal leishmaniasis (PKDL) appears as a rash in some individuals who have recovered from visceral leishmaniasis caused by Leishmania donovani. Today, basic knowledge of this neglected disease and how to predict its progression remain largely unknown. METHODS AND
findingsThis study addresses the use of several biochemical, haematological and immunological variables, independently or through unsupervised machine learning (ML), to predict PKDL progression risk. In 110 patients from Sudan, 31 such factors were assessed in relation to PKDL disease state at the time of diagnosis: progressive (worsening) versus stable. To identify key factors associated with PKDL worsening, we used both a conventional statistical approach and multivariate analysis through unsupervised ML. The independent use of these variables had limited power to predict skin lesion severity in a baseline examination. In contrast, the unsupervised ML approach identified a set of 10 non-redundant variables that was linked to a 3.1 times higher risk of developing progressive PKDL. Three of these clustering factors (low albumin level, low haematocrit and low IFN-γ production in PBMCs after Leishmania antigen stimulation) were remarkable in patients with progressive disease. Dimensionality re-establishment identified 11 further significantly modified factors that are also important to understand the worsening phenotype. Our results indicate that the combination of anaemia and a weak Th1 immunological response is likely the main physiological mechanism that leads to progressive PKDL.
conclusionsA combination of 14 biochemical variables identified by unsupervised ML was able to detect a worsening PKDL state in Sudanese patients. This approach could prove instrumental to train future supervised algorithms based on larger patient cohorts both for a more precise diagnosis and to gain insight into fundamental aspects of this complication of visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.